#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	13666	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2100	641.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1418	1418	C	795	C	769	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	13666	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2100	641.7	0	HET	.	.	.	G298A	.	298	298	G	532	532	G	718	G,A	554,129	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	13666	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2100	641.7	0	HET	.	.	.	A69G	.	69	69	A	303	303	A	814	A,G	456,319	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25224	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3459	721.4	0	.	n	.	0	T695C	SNP	695	695	T	1019	1019	C	756	C,T	734,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25224	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3459	721.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1661	1661	A	877	A,G	762,78	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25224	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3459	721.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2295	2295	C	761	C,T,G,A	713,1,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25224	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3459	721.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2369	2369	A	711	A	690	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25224	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3459	721.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	2921	2921	C	722	C,G	692,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	1802	folP	855	855	100.0	folP.l15.c4.ctg.1	1451	123.0	1	SNP	p	R229S	1	.	.	685	687	AGC	1010	1012	AGC	183;185;187	A;G;C	179;180;179	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4916	gyrA	2751	2751	99.85	gyrA.l6.c30.ctg.1	3182	152.4	1	SNP	p	S91F	1	.	.	271	273	TTC	492	494	TTC	173;171;169	T;T,C;C	164;162,1;162	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4916	gyrA	2751	2751	99.85	gyrA.l6.c30.ctg.1	3182	152.4	1	SNP	p	G95N	0	.	.	283	285	GGC	504	506	GGC	165;164;161	G;G,C,A;C	161;157,1,1;154	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4916	gyrA	2751	2751	99.85	gyrA.l6.c30.ctg.1	3182	152.4	1	SNP	p	D95G	1	.	.	283	285	GGC	504	506	GGC	165;164;161	G;G,C,A;C	161;157,1,1;154	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1532	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1369	110.3	1	SNP	p	G45D	0	.	.	133	135	GGC	429	431	GGC	170;169;166	G;G;C	162;161;158	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	736	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c30.ctg.1	821	88.4	0	.	n	.	0	A197.	DEL	197	197	A	465	465	A	173	A	167	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4554	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3078	146.6	1	SNP	p	D86N	0	.	.	256	258	GAC	664	666	GAC	177;175;175	G;A,C;C	174;164,1;172	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4554	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3078	146.6	1	SNP	p	S87R	1	.	.	259	261	CGT	667	669	CGT	174;171;175	C;G;T	170;169;167	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4554	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3078	146.6	1	SNP	p	R87I	0	.	.	259	261	CGT	667	669	CGT	174;171;175	C;G;T	170;169;167	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4554	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3078	146.6	1	SNP	p	R87W	0	.	.	259	261	CGT	667	669	CGT	174;171;175	C;G;T	170;169;167	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4554	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3078	146.6	1	SNP	p	S88P	0	.	.	262	264	TCC	670	672	TCC	174;173;174	T;C;C	167;167;168	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4028	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2636	151.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1607	1609	GGC	200;199;200	G;G;C	193;192;189	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	155	3556	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2283	147.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1276	1278	GCA	175;172;174	G,C;C,A;A,C	163,1;159,1;162,2	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	155	3556	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2283	147.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1279	1281	ATC	176;176;176	A,C;T;C,G	165,1;161;165,2	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	155	3556	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2283	147.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1291	1293	GTG	167;165;164	G,A;T,C;G,C	159,2;154,2;156,2	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	155	3556	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2283	147.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1291	1293	GTG	167;165;164	G,A;T,C;G,C	159,2;154,2;156,2	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	155	3556	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2283	147.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1795	1797	ACC	155;154;157	A,C;C;C	147,1;151;154	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	155	3556	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2283	147.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1849	1851	GCG	145;146;147	G;C;G,C	136;118;136,1	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	155	3556	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2283	147.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1849	1851	GCG	145;146;147	G;C;G,C	136;118;136,1	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	155	3556	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2283	147.3	1	SNP	p	G543S	1	.	.	1627	1629	AGC	1972	1974	AGC	156;154;152	A,G;G;C,T	146,5;150;143,5	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	155	3556	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2283	147.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1981	1983	GGC	146;145;146	G,A;G;C	137,4;140;139	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	155	3556	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2283	147.3	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1999	2001	CCG	119;123;123	C,G;C;G,C	100,2;106;105,1	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	155	3556	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2283	147.3	0	HET	.	.	.	C417T	.	417	417	C	762	762	C	192	C,T	159,25	.	.
penA.5.002	penA.5.002	1	1	155	3556	penA	1752	1752	100.0	penA.l6.c17.ctg.1	2283	147.3	0	HET	.	.	.	T411C	.	411	411	T	756	756	T	201	T,C	169,23	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5308	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3139	167.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1622	1624	CCG	181;182;182	C;C;G	164;171;166	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2174	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1883	114.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	589	589	C	145	C	134	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	224	porB1a	984	285	90.31	porB1a.l6.c30.ctg.1	1102	17.9	0	.	p	.	0	H217N	NONSYN	649	651	CAT	842	844	AAT	19;19;19	A;A;T	19;19;19	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	224	porB1a	984	285	90.31	porB1a.l6.c30.ctg.1	1102	17.9	0	.	p	.	0	D218N	NONSYN	652	654	GAT	845	847	AAT	19;19;19	A;A;T	19;19;19	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	224	porB1a	984	285	90.31	porB1a.l6.c30.ctg.1	1102	17.9	0	.	p	.	0	V226A	NONSYN	676	678	GTA	869	871	GCA	16;16;16	G;C;A	16;16;16	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	224	porB1a	984	285	90.31	porB1a.l6.c30.ctg.1	1102	17.9	0	.	p	.	0	.	MULTIPLE	700	702	ACT	892	894	GTA	14;13;13	G;T;A	14;12;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	224	porB1a	984	285	90.31	porB1a.l6.c30.ctg.1	1102	17.9	0	.	p	.	0	S236N	NONSYN	706	708	AGC	898	900	AAC	13;13;13	A;A;C	13;13;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	224	porB1a	984	285	90.31	porB1a.l6.c30.ctg.1	1102	17.9	0	.	p	.	0	.	MULTIPLE	709	711	AAC	902	906	TGGCG	12;12;13;12;12	T;G;G;C;G	12;12;13;11;12	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	224	porB1a	984	285	90.31	porB1a.l6.c30.ctg.1	1102	17.9	0	.	p	.	0	D238A	NONSYN	712	714	GAT	908	910	GCT	14;17;22	G;C;T	14;16;20	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	224	porB1a	984	285	90.31	porB1a.l6.c30.ctg.1	1102	17.9	0	.	p	.	0	V258L	NONSYN	772	774	GTA	968	970	TTA	39;40;40	T,G;T;A	38,1;39;40	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	224	porB1a	984	285	90.31	porB1a.l6.c30.ctg.1	1102	17.9	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	1013	1015	CAT	34;32;32	C,G;A;T	30,2;30;30	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	224	porB1a	984	285	90.31	porB1a.l6.c30.ctg.1	1102	17.9	0	.	p	.	0	D274S	NONSYN	820	822	GAT	1016	1018	AGT	32;32;32	A,G;G,A;T	28,2;28,2;30	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	224	porB1a	984	285	90.31	porB1a.l6.c30.ctg.1	1102	17.9	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	1025	1027	TAC	31;31;32	T,C;A;C	28,2;28;29	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	667	2504	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1334	180.7	0	.	p	.	0	N38E	NONSYN	112	114	AAT	272	274	GAA	202;203;204	G,A;A;A	194,1;195;194	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	667	2504	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1334	180.7	0	.	p	.	0	N134D	NONSYN	400	402	AAT	560	562	GAT	214;216;216	G,A;A;T	187,17;207;204	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	667	2504	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1334	180.7	0	.	p	.	0	P175S	NONSYN	523	525	CCA	683	685	TCA	189;191;189	T;C;A	178;181;182	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	667	2504	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1334	180.7	0	.	p	.	0	D212N	NONSYN	634	636	GAT	794	796	AAT	183;182;181	A;A;T	171;171;162	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	667	2504	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1334	180.7	0	.	p	.	0	A218V	NONSYN	652	654	GCC	812	814	GTC	169;174;173	G,A;T;C	157,2;159;170	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	667	2504	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1334	180.7	0	.	p	.	0	F222S	NONSYN	664	666	TTT	824	826	TCT	179;180;181	T;C,T;T	174;161,17;179	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	667	2504	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1334	180.7	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1142	1144	GCA	215;216;221	G;C,A;A	206;184,22;211	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	667	2504	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1334	180.7	1	SNP	p	G120K	1	.	.	358	360	AAG	518	520	AAG	213;215;216	A;A;G	207;208;209	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	667	2504	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1334	180.7	1	SNP	p	A121D	1	.	.	361	363	GAC	521	523	GAC	212;211;208	G,A;A;C	188,17;205;203	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	667	2504	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1334	180.7	1	SNP	p	D121N	0	.	.	361	363	GAC	521	523	GAC	212;211;208	G,A;A;C	188,17;205;203	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	667	2504	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1334	180.7	0	HET	.	.	.	G219A	.	219	219	G	379	379	G	225	G,A	182,31	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	667	2504	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1334	180.7	0	HET	.	.	.	G223A	.	223	223	G	383	383	G	222	G,A	182,30	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	667	2504	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1334	180.7	0	HET	.	.	.	G160T	.	160	160	G	320	320	G	213	G,T	180,23	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	8942	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4818	183.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1114	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1078	102.4	1	SNP	p	V57M	1	.	.	169	171	ATG	555	557	ATG	236;236;238	A;T,A;G	228;225,1;226	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
